Streetbeat News

Insider Trading

RVP

SHWZ

TLRY

Insiders at Retractable Technologies, Tilray Brands, and Medicine Man Technologies have recently purchased shares of their respective companies, signaling potential confidence in their future prospects. Retractable Technologies' CEO acquired shares at $1.14 each, despite the company reporting an operational loss for the first nine months of 2023. Tilray Brands saw purchases by its President and CEO, CFO, and Global General Counsel, following an agreement with Double Diamond Holdings. Medicine Man Technologies' Chief Legal Officer also bought shares, with the company reporting an 8% revenue increase in Q3.

Portfolio Pulse from Avi Kapoor

January 16, 2024 | 2:36 pm

AFRM

BABA

CFLT

Jim Cramer commented on several companies during CNBC's 'Mad Money Lightning Round.' He described Confluent, Inc.'s (CFLT) recent quarter as 'miserable' and suggested it's in the 'penalty box,' advising to wait two quarters before considering it as a buy. Cramer was negative on Alibaba Group Holding Limited (BABA), in light of recent criticism of Congress member Laurel Lee's stock trading. He warned against shorting Affirm Holdings, Inc. (AFRM), citing the company's popularity and CEO's intelligence. Cramer also expressed a reluctance to recommend Altria Group, Inc. (MO), a tobacco company. The mentioned stocks experienced slight declines in their share prices during Friday's session.

Portfolio Pulse from Avi Kapoor

January 16, 2024 | 1:07 pm

AXR

CSBR

SLDB

Insiders at Solid Biosciences, Champions Oncology, and AMREP Corporation have made notable stock purchases. Solid Biosciences insiders acquired over 4 million shares, coinciding with a private placement deal. Champions Oncology's director bought shares after a reported loss, and AMREP's 10% owner invested following a sales decline. Insider buying can signal confidence in the company's future or undervaluation, potentially indicating a buying opportunity, though it should not be the sole investment decision factor.

Portfolio Pulse from Avi Kapoor

January 16, 2024 | 11:17 am

MSTR

Michael Saylor, co-founder of MicroStrategy Inc. (NASDAQ:MSTR), sold between 3,882 and 5,000 shares of the company, netting over $20 million, ahead of the SEC's approval of Bitcoin ETFs. This marks his first share sale in nearly 12 years, which is part of a pre-existing plan to potentially sell up to 400,000 shares by April 26. MicroStrategy's stock has declined by 23% since the year's start, partly due to the introduction of Bitcoin ETFs potentially making its shares less attractive as a Bitcoin proxy. The company's Bitcoin holdings are currently valued at around $8.3 billion, a 40% paper gain.

Portfolio Pulse from Bibhu Pattnaik

January 14, 2024 | 3:01 pm

BRK

DJCO

Berkshire Hathaway Inc. (BRK) board member Chris Davis warns of potential activist investor pressure after CEO Warren Buffett's departure. Buffett, 93, is nearing the end of his tenure, following the death of his right-hand man, Charlie Munger. Davis praises Buffett and Munger's stewardship and expresses concern over future shareholder proposals that may seek short-term value at the expense of long-term gains. Berkshire's structure, designed by Buffett and Munger, faces scrutiny for efficiency, which could lead to calls for changes. The Daily Journal Corp. (DJCO) also acknowledges the irreplaceable role of Munger in its operations.

Portfolio Pulse from Rounak Jain

January 13, 2024 | 6:38 am

CMG

Senator John W Hickenlooper sold between $100,001 and $250,000 worth of Chipotle Mexican Grill (NYSE:CMG) stock on January 11, 2024, as reported by a Periodic Transaction Report from the U.S. Senate. Chipotle's shares were trading at $2276.51 with no change at the time of the report. Congressional transactions are not primary indicators for investing decisions but can be considered by investors. The STOCK Act prevents Congress members from using non-public information for personal gain in stock transactions.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 3:05 pm

SCHW

Georgia Representative Rick Allen reported purchasing Charles Schwab (NYSE:SCHW) stock valued between $50,001 and $100,000 on January 11, 2024. The shares of Charles Schwab were trading up 0.38% at $65.51 at the time of the report. Congressional transactions are monitored under the STOCK Act, which prohibits the use of non-public information for personal gain and requires prompt disclosure of their trades.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 3:05 pm

AYI

BOX

NTAP

QCOM

Insiders at Qualcomm, NetApp, Box, and Acuity Brands have recently sold shares of their companies. Qualcomm's CCO sold 1,000 shares, NetApp's CFO sold 15,000 shares, Box's CFO and Controller sold a combined 20,750 shares, and Acuity Brands' SVP & General Counsel sold 1,900 shares. These sales occurred amidst various company-specific news such as product announcements, analyst ratings, and financial results.

Portfolio Pulse from Avi Kapoor

January 12, 2024 | 1:49 pm

ENTX

FRTX

OPK

VGZ

Insiders at four companies have recently made notable purchases of their own company's stock. Entera Bio Ltd. (ENTX) Director Haya Taitel bought shares at $0.77 each after the company received an extension from Nasdaq to regain compliance. OPKO Health, Inc. (OPK) 10% owner Frost Gamma Investments Trust purchased shares at $0.94 each following the pricing of a $200 million convertible notes offering. Fresh Tracks Therapeutics, Inc. (FRTX) 10% owner Exploration Capital LLC acquired shares at $0.98 each as the company plans a special meeting to seek approval of liquidation. Vista Gold Corp. (VGZ) Director Tracy Austin Stevenson bought shares at $0.37 each after the company announced a $20 million royalty agreement with Wheaton Precious Metals.

Portfolio Pulse from Avi Kapoor

January 12, 2024 | 12:48 pm

ADC

DYN

EYPT

Insider purchases at Dyne Therapeutics, EyePoint Pharmaceuticals, and Agree Realty indicate confidence in these companies. Dyne Therapeutics' 10% owner Dirk Kersten acquired shares worth $30M following a $300M public stock offering. EyePoint Pharmaceuticals' 10% owner bought shares for $17.05M, and Agree Realty's Director purchased shares worth approximately $657K. Insider trading can signal investment opportunities but should not be the sole decision factor.

Portfolio Pulse from Avi Kapoor

January 12, 2024 | 11:38 am